原发性干燥综合征肾损害药物治疗进展

Advances in the drug treatment for the renal impairment of primary Sj?gren's syndrome

原发性干燥综合征(pSS)是一种进展性的自身免疫性疾病,以口眼干燥和系统损害为特点。pSS肾损害很常见,临床上选择糖皮质激素及其他免疫抑制剂治疗pSS肾损害可获得一定疗效;此外生物制剂也相继开发如利妥昔单抗的治疗等得到较大进展;还有许多在研的新药,从免疫病理机制出发,有很好的应用前景。本文综述pSS的药物治疗及潜在治疗靶点的研究进展。

Primary Sjogren＇s syndrome（pSS） is a progressive autoimmune disease characterized by xerostomia and systemic impairment, in which the renal impairment is common. The glucocorticoid and other immunosuppressive agents including the biological agents such as rituximab can be used to treat renal impairment of pSS. Recently, based on immunopathological mechanism several new drugs which have good application prospects are under developing. This review summarizes the research progress of drug therapy and potential therapeutic targets of pSS.